The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
Year: 2023
Type: article
Abstract: Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions (cytotoxic chemotherapy, targeted therapies, immunotherapy, and radiotherapy). Further, skin toxicities can lead to interruption or even discontinuation of anticancer treatment in some patients, translating to suboptimal outcomes. Dermocosmetics (or cosmeceuticals)-defined as skincare solutions incorporating dermatologically active ingredients (beyond vehicle effects) that directly improve symptoms of various skin conditions-are increasingly being used in cancer care to prevent and manage skin toxicities. The active ingredients in these products have a measurable biological action in skin; they typically improve skin integrity (barrier function/hydration and other factors) while relieving skin symptoms. The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) partnered to select a multidisciplinary group of healthcare professionals involved in the management of patients with cancer and skin toxicities. The group reviewed existing literature and created a summary of recommendations for managing these toxicities through online meetings and communication. In this publication, the group (1) reviews new skin toxicities seen with oncology drugs and (2) evaluates the role of dermocosmetics in improving patient outcomes and minimizing cancer treatment interruptions. We provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.
Source: Supportive Care in Cancer
Institutions: Centre National de la Recherche Scientifique, Inserm, Immunologie et Nouveaux Concepts en Immunothérapie, Nantes Université, The University of Queensland, Hospital Alemão Oswaldo Cruz, University of Rochester Medicine, University of Rochester, Allegheny Health Network, Drexel University, Université de Yaoundé I, Yaoundé General Hospital, Université Paris-Sud, Institut Gustave Roussy, Fondation Gustave Roussy, Shanghai Jiao Tong University, Ruijin Hospital, Multinational Association of Supportive Care in Cancer, Association Francophone pour les Soins Oncologiques de Support, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,290
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4388333539